136 related articles for article (PubMed ID: 35081567)
1. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer.
Omiya K; Oba A; Inoue Y; Kobayashi K; Wu YHA; Ono Y; Sato T; Sasaki T; Ozaka M; Sasahira N; Ito H; Saiura A; Takahashi Y
Ann Surg; 2023 Jun; 277(6):e1278-e1283. PubMed ID: 35081567
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5792-5800. PubMed ID: 37248377
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Usefulness in Patients with Normal CA19-9.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5801-5802. PubMed ID: 37355518
[TBL] [Abstract][Full Text] [Related]
6. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer.
Sunagawa Y; Yamada S; Sato Y; Morimoto D; Sonohara F; Takami H; Inokawa Y; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Ann Surg Oncol; 2020 Jun; 27(6):2081-2089. PubMed ID: 31673938
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
8. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
[TBL] [Abstract][Full Text] [Related]
9. DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Hasegawa S; Takahashi H; Akita H; Mukai Y; Mikamori M; Asukai K; Yamada D; Wada H; Fujii Y; Sugase T; Yamamoto M; Takeoka T; Shinno N; Hara H; Kanemura T; Haraguchi N; Nishimura J; Matsuda C; Yasui M; Omori T; Miyata H; Ohue M; Ishikawa O; Sakon M
BMC Cancer; 2023 Jan; 23(1):63. PubMed ID: 36653747
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
11. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
15. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
16. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
17. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment.
Ushida Y; Inoue Y; Ito H; Oba A; Mise Y; Ono Y; Sato T; Saiura A; Takahashi Y
Pancreatology; 2021 Jan; 21(1):130-137. PubMed ID: 33303373
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.
Kawa S; Oguchi H; Kobayashi T; Tokoo M; Furuta S; Kanai M; Homma T
Br J Cancer; 1991 Nov; 64(5):899-902. PubMed ID: 1931612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
